|
| 37503080 | Contextualizing protein representations using deep learning on protein networks and single-cell data. | bioRxiv | 2024 |
| 36720220 | The landscape of immune dysregulation in Crohn's disease revealed through single-cell transcriptomic profiling in the ileum and colon. | Immunity | 2023 |
| 36040554 | Endogenous Levels of Circulating Androgens Are Not Associated with Risk of Microscopic Colitis. | Dig Dis Sci | 2023 |
| 35579793 | E-cigarette Use and Disease Outcomes in Inflammatory Bowel Diseases: A Case-Control Study. | Digestive Diseases and Sciences | 2023 |
| 36114766 | Histologic Activity in an Endoscopically Normal-Appearing Pouch Predicts Future Risk of Pouchitis in Patients With Ulcerative Colitis. | American Journal of Gastroenterology | 2023 |
| 37663925 | Economic Burden of Fatigue in Inflammatory Bowel Disease. | Crohns Colitis 360 | 2023 |
| 37579866 | Risk of Cancer Recurrence in Patients With Immune-Mediated Diseases With Use of Immunosuppressive Therapies: An Updated Systematic Review and Meta-Analysis. | | 2023 |
| 37802268 | Progression of Pediatric Crohn's Disease Is Associated With Anti-Tumor Necrosis Factor Timing and Body Mass Index Z-Score Normalization. | | 2023 |
| 37572861 | Geographic Inequities in Access to Phase 3 Clinical Trials for Inflammatory Bowel Disease in the United States. | | 2023 |
| 37781885 | Periodontal disease is not associated with risk of inflammatory bowel disease: Results from two prospective cohort studies in the US. | | 2023 |
| 37031712 | Comparative Effectiveness of Upadacitinib and Tofacitinib in Inducing Remission in Ulcerative Colitis: Real-World Data. | | 2023 |
| 37080587 | Genetic coding variant in complement factor B (CFB) is associated with increased risk for perianal Crohn's disease and leads to impaired CFB cleavage and phagocytosis. | Gut | 2023 |
| 36823301 | Gut microbial metabolism of 5-ASA diminishes its clinical efficacy in inflammatory bowel disease. | Nat Med | 2023 |
| 36822736 | AGA Clinical Practice Guideline on the Role of Biomarkers for the Management of Ulcerative Colitis. | Gastroenterology | 2023 |
| 37453593 | Is it Time for the Alternative to Move to the Mainstream? | | 2023 |
| 37197708 | Longitudinal trajectories of anxiety, depression, and bipolar disorder in inflammatory bowel disease: a population-based cohort study. | | 2023 |
| 36753033 | Mild Crohn's Disease: Definition and Management. | Curr Gastroenterol Rep | 2023 |
| 36752797 | Remodeling of colon plasma cell repertoire within ulcerative colitis patients. | J Exp Med | 2023 |
| 36480719 | Editorial: immunosuppression and SARS-CoV-2 vaccination-where do we stand? | | 2023 |
| 37443254 | Leveraging polygenic enrichments of gene features to predict genes underlying complex traits and diseases. | Nat Genet | 2023 |
| 36993194 | Mapping the dynamic genetic regulatory architecture of <i>HLA</i> genes at single-cell resolution. | medRxiv | 2023 |
| 37296268 | Content Validity and Psychometric Evaluation of the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) in Patients with Crohn's Disease and Ulcerative Colitis. | Pharmacoecon Open | 2023 |
| 36731590 | Food Processing and Risk of Inflammatory Bowel Disease: AÂ Systematic Review and Meta-Analysis. | Clin Gastroenterol Hepatol | 2023 |
| 36662167 | Serum Lipidomic Screen Identifies Key Metabolites, Pathways, and Disease Classifiers in Crohn's Disease. | Inflamm Bowel Dis | 2023 |
| 37224301 | A Narrative Review of Financial Burden, Distress, and Toxicity of Inflammatory Bowel Diseases in the United States. | Am J Gastroenterol | 2023 |
| 34473269 | Alcohol Consumption is Associated With An Increased Risk of Microscopic Colitis: Results From 2 Prospective US Cohort Studies. | Inflamm Bowel Dis | 2022 |
| 36038634 | Large-scale sequencing identifies multiple genes and rare variants associated with Crohn's disease susceptibility. | Nat Genet | 2022 |
| 35762697 | Precision medicine: how multiomics will shape the future of inflammatory bowel disease? | Current Opinion in Gastroenterology | 2022 |
| 35644164 | Upadacitinib for ulcerative colitis. | Lancet, The | 2022 |
| 35487235 | Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases: an International Organization for Study of Inflammatory Bowel Diseases consensus. | Lancet Gastroenterol Hepatol | 2022 |
| 35732730 | Depression and anxiety in inflammatory bowel disease: epidemiology, mechanisms and treatment. | Nature Reviews Gastroenterology and Hepatology | 2022 |
| 35416799 | Recommendations on the Appropriate Management of Steroids and Discharge Planning During and After Hospital Admission for Moderate-Severe Ulcerative Colitis: Results of a RAND Appropriateness Panel. | Am J Gastroenterol | 2022 |
| 35854436 | Comorbidity Influences the Comparative Safety of Biologic Therapy in Older Adults With Inflammatory Bowel Diseases. | Am J Gastroenterol | 2022 |
| 36439135 | Vedolizumab for acute gastrointestinal graft-versus-host disease: A systematic review and meta-analysis. | Frontiers in Immunology | 2022 |
| 36591609 | Lifestyle factors for the prevention of inflammatory bowel disease. | Gut | 2022 |
| 36498541 | Comparative Safety of Ustekinumab and Vedolizumab in Older Patients with Inflammatory Bowel Disease: A Bicentric Cohort Study. | | 2022 |
| 34117949 | High Anti-Infliximab Antibody Titers Do Not Impact Response to Subsequent Adalimumab Treatment in Inflammatory Bowel Diseases. | Digestive Diseases and Sciences | 2022 |
| 33775898 | Dietary Gluten Intake Is Not Associated With Risk of Inflammatory Bowel Disease in US Adults Without Celiac Disease. | Clin Gastroenterol Hepatol | 2022 |
| 33932198 | Inflammatory Bowel Disease Patients Who Respond to Treatment with Anti-tumor Necrosis Factor Agents Demonstrate Improvement in Pre-treatment Frailty. | Digestive Diseases and Sciences | 2022 |
| 33065312 | Vedolizumab or Tumor Necrosis Factor Antagonist Use and Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease With Prior Malignancy: A Retrospective Cohort Study. | Clinical Gastroenterology and Hepatology | 2022 |
| 35277863 | A United States expert consensus to standardise definitions, follow-up, and treatment targets for extra-intestinal manifestations in inflammatory bowel disease. | Aliment Pharmacol Ther | 2022 |
| 34461300 | Ultra-processed Foods and Risk of Crohn's Disease and Ulcerative Colitis: A Prospective Cohort Study. | Clin Gastroenterol Hepatol | 2022 |
| 35031525 | Risk Factors for Incident Inflammatory Bowel Disease According to Disease Phenotype. | Clin Gastroenterol Hepatol | 2022 |
| 34902573 | Sugars and Gastrointestinal Health. | Clinical Gastroenterology and Hepatology | 2022 |
| 35189386 | IOIBD Recommendations for Clinical Trials in Ulcerative Proctitis: The PROCTRIAL Consensus. | Clin Gastroenterol Hepatol | 2022 |
| 34662575 | Plasma concentrations of perfluoroalkyl substances and risk of inflammatory bowel diseases in women: A nested case control analysis in the Nurses' Health Study cohorts. | Environ Res | 2022 |
| 34433783 | Early Change in Fecal Calprotectin Predicts One-Year Outcome in Children Newly Diagnosed With Ulcerative Colitis. | J Pediatr Gastroenterol Nutr | 2022 |
| 35134899 | Fecal Calprotectin Is a Predictor of Need for Rescue Therapy in Hospitalized Severe Colitis. | Inflammatory Bowel Diseases | 2022 |
| 35113275 | Comparative Risk of Thrombotic and Cardiovascular Events with Tofacitinib and Anti-TNF Agents in Patients with Inflammatory Bowel Diseases. | Dig Dis Sci | 2022 |
| 34881819 | Alcohol consumption and risk of inflammatory bowel disease among three prospective US cohorts. | Aliment Pharmacol Ther | 2022 |